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ABSTRACT 
Background: Novel predictive markers are needed to accurately diagnose the breast cancer 
patients so they do not need to undergo any unnecessary aggressive therapies. Various gene 
expression studies based predictive gene signatures have generated in the recent past to predict 
the binary estrogen-receptor subclass or to predict the therapy response subclass. However, the 
existing algorithms comes with many limitations, including low predictive performances over 
multiple cohorts of patients and non-significant or limited biological roles associated with the 
predictive gene signatures. Therefore, the aim of this study is to develop novel predictive markers 
with improved performances. 
Methods: We propose a novel prediction algorithm called IPA to construct a predictive gene 
signature for performing multiple prediction tasks of predicting estrogen-receptor based binary 
subclass and predicting chemotherapy response (neoadjuvantly) based binary subclass. The 
constructed gene signature with considering multiple classification techniques was used to 
evaluate the algorithm performance on multiple cohorts of breast cancer patients. 
Results: The evaluation on multiple validation cohorts demonstrated that proposed algorithm 
achieved stable and high performance to perform prediction tasks, with consideration given to 
any classification techniques. We show that the predictive gene signature of our proposed 
algorithm reflects the mechanisms underlying the estrogen-receptors or response to therapy with 
significant greater biological interpretations, compared with the other existing algorithm.  
Keywords: estrogen receptor, pathologic complete response, chemotherapy, gene expression, 
prediction, network. 
1. INTRODUCTION 
Breast cancer is believed as the most common type of cancer and the second leading cause of 
cancer death among women in the United States. The prime cause of breast cancer death comes 
from its distant metastasis and recurrence [1]. The diagnosis of breast cancer in the early stage or 
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the treatment response prediction remains one of the significant challenges, and are yet to achieve. 
Therefore, to achieve an improved survival rate among breast cancer patients, it is essential to 
accurately predict the molecular subtypes of breast cancers or the therapy (such as chemotherapy, 
hormonal therapy) responsiveness outcomes.  
The development of microarray gene expression profiling of cancers showed the new strategy that 
allowed the discovery of new biomarkers for cancer diagnosis, prognosis and treatment [2]. These 
biomarkers generally consists of a set of informative genes, called gene signatures. 
In the recent years, a number of methods [3-10] have been developed using microarray gene 
expressions to identify the gene signatures that could be used for diagnose, prognose, or treatment 
response prediction among breast cancer patients. However, some of these existing methods have 
shown promising results with considering limited number of patient cohorts, but failed to achieve 
similar performance in additional validation studies [10]. In addition, their gene signatures were not 
indicative of a gene’s role in the biological mechanisms underlying the breast cancer for the tasks 
of diagnosis, prognosis or treatment response. Evaluating the biological significance from gene 
expression profiling remains a critical challenge [11]. Thus, predictive markers with robust 
performance over multiple cohorts and improved biological insights for different predictive tasks 
are critical factors for translating them into clinical practice, and still remains elusive [10].   
For performing the various prediction tasks for breast cancer, [12] indicate that a cancer originates 
from the driver genes that rapidly alters the expressions in genes that interacts with the driver gene, 
and is therefore good to consider the network based approach for the reasons, including the 
networks based approach shows higher reproducibility across different cohorts compared with non-
network based approach, and the network based approach shows higher accuracy in performing the 
prediction tasks. Various network based approach have been developed for performing different 
prediction tasks [4, 12].   
Although, the network based approaches are effective in performing the prediction tasks. These 
approaches has one major issues, i.e., the existing protein interaction datasets contain many false-
positive interactions (the interactions showed in the experimental dataset but never happens 
biologically), which may cause these interaction datasets biased in discovering the biological 
knowledge [9]. In other words, the identification of reliable interactions from the experimental 
protein interaction datasets is one of the most challenging tasks that are yet to be resolve (see [13] 
for details). While some studies showed the network based approach are effective, the other studies 
showed the non-network based approaches are effective in performing the prediction tasks. There 
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is no general consensus on which approach is most effective over the other, and this is one of the 
potential aims of the current study to discover which approach is better for performing different 
prediction tasks. 
In this paper, we propose a novel computational predictive algorithm, called Integrated Predictive 
Algorithm (IPA) for performing multiple prediction tasks, including predicting estrogen-receptor 
based binary subclass and predicting chemotherapy response (neoadjuvantly) based binary 
subclass. First, from the training cohort, 2-fold cross-validation was performed to extract the 
predictive gene signatures to avoid over-fitting, and then different classification techniques were 
incorporated for an algorithm to predict the binary subclasses. Since the performance of the 
prediction algorithm may vary with different classification techniques, this is the reason that we 
considered multiple classification techniques, including TreeBoost; decision tree (DT); support 
vector machine with Linear kernel, Sigmoid kernel, and RBF kernel (SVM-L, SVM-S, SVM-
RBF); diagonal linear discriminant analysis (DLDA); the logistic regression model (LR) [14]. 
Next, we considered the multiple performance measures to further demonstrate the independency 
of algorithm for the performance measures. Further, the proposed algorithm was constructed using 
the network based information, called network based IPA algorithm (N-IPA). The performances of 
the proposed algorithm was evaluated comparing with the Ttest algorithm constructed for 
performing the binary prediction tasks. 
The evaluation of the proposed algorithm demonstrates their robust and stable performances across 
different cohorts of patients and also outperformed the Ttest algorithm with consideration given to 
any classification technique. Moreover, the predictive gene signature of the proposed algorithm 
reflects that the biological meaning of the gene signatures is significant and relates to the 
mechanisms underlying estrogen-receptor or chemotherapy response based prediction task. 
This paper is organized as follows. The proposed algorithm is defined in Section 2. The training 
and validation cohorts used in this study, statistical validation with patient prediction results, and 
biological validation are presented in Section 3. Finally, we conclude this paper in Section 4. 
2. METHODS 
2.1 Integrated Predictive Algorithm 
The aim of the proposed algorithm is to construct the gene signature that can predict the binary 
subclass of estrogen receptors and the neoadjuvant breast cancer patient response to standard 
chemotherapy regimens. In other words, this problem can be considered as the binary class 
prediction problem, i.e., predicting estrogen-receptor positive (ERp) and estrogen-receptor negative 
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(ERn), or predicting pathological complete response (with no residual cancer or lymph-node 
involved) (pCR) and non-pathological complete response (residual cancer) (npCR). 
The ERn subtype is considered as the aggressive form of breast cancer compared with ERp subtype 
[15, 16]. Also, patients with ERn subtype achieved higher pCR rates to standard chemotherapy 
regimens (treated neoadjuvantly), compared with their counterpart ERp subtype [17]. Therefore, 
based on the above ideas, for predicting the binary subclass, we proposed two scoring metrics for 
each gene in the gene expression dataset (see Table 1 for illustration of gene expression dataset) as: 
δ =	μ,
 −	μ,
  
σ =	µ,
 −	µ,
         (1) 
here,μ,
 =	∑ 

∈,
  ; 
 defines expression of gene g in ith sample, N defines the total number of samples with their 
labels belongs to pCR and ERn. The prime idea for the equation (1) is to identify the differential 
expression (DE) pattern of estrogen receptor subclass with considering the chemotherapy response 
based subclass. Here, δ	represents the estrogen-receptor based differential expression effectiveness 
score with respect to pCR and σ	represents the estrogen-receptor based differential expression 
effectiveness score with respect to npCR. 
However, as defined above, we are interested in identifying the genes with their positive or 
negative δ and σ based two-scoring metric. In other words, If (δ > 0 andσ > 0) or (δ < 0 andσ <
0) then gene  has DE strength between subclasses and remained in the dataset; else gene  is 
removed/filtered from the dataset.  
Table 1: Illustration of microarray gene expression dataset incorporated in this study 
Chemotherapy response (pCR: 1, npCR: 0) 1 1 0  
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Here, ! defines the "#$ gene,  defines the %#$ sample, and  ! defines the gene expression of "#$gene in %#$ sample. 
The remaining number of genes from the above step with their two-scoring metrics of δ and σ were 
then retained to from the discriminative score. The discriminative score or S measure can be 
formed by integrating the δ and σ	scoring metrics that can evaluate the overall DE strength of any 
gene  between ERp and ERn with respect to binary chemotherapy response.The equation (2) 
provides the details for calculating the S measure for a gene  (). 
 =	
'(
)
(*

+, δ
 +	 +. σ		; 	0 ≠ 0;	0 ≠ 0
+, δ
 +	σ		; 			0 ≠ 0;	0 = 0
δ
 +	 +. σ		; 	 		0 = 0;	0 ≠ 0
2
       (2) 
Here, 0 and 0are incorporated to penalize δ andσ, respectively, and represents the number of 
samples in ERp and ERn groups, respectively. With this equation (2), each gene in a dataset is 
assigned anS measure. Since, the values of 0 and 0 vary in different cases, the calculation of 	 
varies accordingly. The higher the	, the higher the DE strength between the two binary classes of 
estrogen-receptor with considering their binary chemotherapy response. Therefore, based on the S 
measure, the significant genes were then identified with p-value <0.05 (using log-rank test), and 
were extracted. These extracted genes form the gene signature. 
Based on the two scoring metrics and the S measure, we named this proposed algorithm Integrated 
Predictive Algorithm for predicting estrogen-receptor and chemotherapy response based binary 
subclasses (IPA). The pseudo-code is shown in Figure 1. 
Initialize:  3 = 	∅//	3 is the temporary list of selected genes 
567 = 	∅ //567 is the set of predicted gene signature   
 
//Two scoring metrics and S measure evaluation  
For any gene g in the dataset D 
{ 
        Evaluate 8 and9 
if (8 > 0 and9 > 0) or (8 < 0 and9 < 0) 
              then generate  measure of gene g 
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and  3 = 	3	 ∪ 		 ;< 
else 
removed/filtered from the dataset D  
} 
 
//identifying significant genes to form IDP gene signature 
For each gene k contained in 3 
{ 
       generate p-Value using log-rank test 
       if p<0.05 
567 = 567 	∪ ;=< 
       else 
             removed/filtered from	3 
} 
return 567 
 
Fig. 1. Pseudo-code of the IPA algorithm. 
2.1.1 Network based IPA Algorithm 
Given n genes and m edges or interactions, the interaction network is defined by G = (V, E), where 
|?| =n and |@| =	m. The S measure (see equation (2)) was then generated for each gene in the 
interaction network, as did for IPA algorithm. Therefore, each interaction y between genes (,	=) is 
then assigned a merged S measure (A) from their interacting genes, which is simply the average of 
S measure between genes	 and=. The generated A measure for each gene interaction was then 
used to identify the significant gene interactions with p-value <0.05 (using log-rank test), and were 
extracted. The genes that participate in these extracted significant gene interactions form the gene 
signature. This algorithm is named network-based integrated predictive algorithm (N-IPA) 
2.2 Classification techniques and performance evaluation 
The IPA gene signature is then used to perform the prediction tasks for the samples by evaluating 
their gene signature effectiveness score (E) as: 
@(C) = 	∑ @(, C) |D|⁄∈F         (3) 
where, N defines the total number of genes in the IPA gene signature, @(C) is the gene signature 
effectiveness score of sample s,and	@(, C) is the expression of gene  in sample s.  
IPA: Integrated Predictive Gene Signature from Gene Expression based Breast Cancer Patient Samples 
Innovative Approach in Stem Cell Research, Cancer Biology and Applied Biotechnology 
ISBN: 978-93-83083-79-4 19 
Using equation (3), each sample s can be transformed into@, which can be used by any of the 
existing classification techniques to perform the binary prediction task. For this study, we 
considered seven widely used classification techniques, including the decision tree (DT); 
TreeBoost; support vector machine with Linear kernel, Sigmoid kernel, and RBF kernel (SVM-L, 
SVM-S, SVM-RBF); the logistic regression (LR) model; and the diagonal linear discriminant 
analysis (DLDA), to evaluate the predictive strength and to show the independency of the 
algorithm on the classification techniques (see Section 3.3 for details).     
Further, if TP represents the number of true positives, TN represents the number of true negatives, 
FP represents the number of false positives, and FN represents the number of false negatives.  
Then, to evaluate the overall performance or the predictive strength of an algorithm, or to 
demonstrate the algorithm independency on the performance measure, three performance measures 
were considered, including,  
Accuracy, evaluated as: ACC = GHIGGHIGIJHIJ;  
F-measure, evaluated as: F-measure = GHGHIJHIJ; and   
the area under ROC curve (AUC) measure, evaluated from the receiver-operating characteristic 
(ROC) curve of sensitivity and 1-specificity for different cut-off points [18, 19]. 
In general, the value of ACC, F-measure, and the AUC is within the range [0, 1], where the value 
of 1 reflects perfect prediction and 0 reflects false prediction. 
3. RESULTS 
3.1 Datasets 
We retrieved two publicly available breast cancer microarray gene expression datasets (GSE20194 
and GSE22226) from the gene expression omnibus (GEO) (http://www.ncbi.nlm.nih.gov/geo/). 
The downloaded microarray datasets were normalized as published by the original studies.  
These datasets were selected based on the availability of estrogen receptor labels, i.e., ERp or ERn, 
and the chemotherapy treatment response labels (treated neoadjuvantly), i.e., pCR (pathological 
complete response with no residual cancer) or npCR (non-pathological complete response with 
residual cancer). The detailed characteristics of each microarray dataset is shown in Table 2. 
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Table 2: Microarray datasets used in this study 
GEO 
accession 
Platform Samples ER (p/n) 
Tumour 
Grade  
(G1/G2/G3) 
Average Age 
in years 
(range) 
Neoadj. 
Chemo. 
regimen 
Response rate 
(pCR/npCR) 
GSE20194 GPL96 278 164/114 13/104/150 51.9 (26-79) TFAC 56/222 
GSE22226 GPL1708 130 65/58 7/52/69 48.17 (28-65) AC or 
AC/T 
32/92 
Abbreviations: ER, estrogen receptor; p=positive; n=negative; TFAC, paclitaxel (T), 5-flourouracil (F), 
doxorubicin (A) and cyclophosphamide (C); AC, doxorubicin (A) and cyclophosphamide (C); AC/T, AC 
plus taxane (T); pCR, pathologic complete response (disease-free); npCR, non-pathologic complete 
response (residual disease). 
 
 
The probe identifier in the cohorts were then converted to gene symbol, as indicated by [20]. In the 
case when multiple probes mapped the same gene symbol, then the median of the probes was 
considered to avoid any overestimation that comes with considering the single gene. Following 
this, the probes with “AFFX” were deleted, as there were no associated genes for these probes. 
Since, the samples are limited in size if considering the individual dataset with their binary ER 
label or their binary chemotherapy response label. Therefore, we integrated the two microarray 
datasets, as shown in Table 2. However, before integrating the datasets, the following steps were 
performed. First, the gene expression values of each dataset were normalised (or re-scaled) 
individually using the formula: 
@K() =	 LM
(N)O	LPQ	(N)
LPRS	(N)O	LPQ	(N)         (4) 
where, @() expresses the TU gene expression value for the ith sample, @V	() and @VWX	() 
represents the minimum and maximum gene expression value for gene  [21]. With this 
normalization measure (4), the gene expressions generated from varied protocols mapped into a 
uniform framework to reduce the impact of varied protocols on the data integration. Compared 
with the original data, we did not observe any significant differences in the normalized gene 
expressions among the study objects.    
Next, a common list of genes from the available microarray datasets with their distinct platforms 
was extracted by cross-referencing each probe annotation in the dataset, and consists of 8,960 
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genes. The cross-referencing was done by the UniGene database [22]. Based on these steps, the 
microarray datasets were then directly integrated to increase the size of the samples and also to 
make the algorithm independent towards the chosen microarray dataset or their platform types.  
From the integrated dataset, the samples with repetitions, missing ER status labels, or missing 
chemotherapy response labels were excluded. 395 samples remained that consists of 225 ERp 
patient samples and 170 ERn patient samples, and 87 pCR patient samples and 308 npCR patient 
samples, respectively.  
3.1.1 Network dataset 
In this study, we incorporated multiple PPI datasets in order to increase the interactions coverage 
that are limited with considering the single protein interaction dataset, including Biological General 
Repository for Interaction Datasets (BIOGRID) [23], INTACT [24], The Molecular Interaction 
Database (MINT) [25], Database of Interacting Proteins (DIP) [26], The Biomolecular Interaction 
Network Database (BIND) [27], and Human Protein Reference Database (HPRD) [28]. The gene 
interaction network were then formed with the genes in the integrated microarray dataset (see 
Section 3.1) from these multiple PPI datasets by considering the Universal Protein Resource 
Database [29]. Once constructed, the self-interactions and the duplicate edges were then removed, 
since they did not have any biological meanings. The resulted gene interaction network contains 
75,553 gene interactions involving 7,706 genes. 
3.2 Two-split dataset to form IPA and N-IPA gene signature 
The integrated dataset was split into two different cohorts according to their ER status labels and 
chemotherapy response labels that contains 197 and 198 samples, respectively, in order to form the 
IPA and N-IPA gene signature. We named these two distinct cohorts as forward cohort (FWC) and 
backward cohort (BWC).Two analysis were then performed by applying the IPA algorithm. First, 
the FWC cohort was used as training set to extract the gene signature, while the BWC cohort was 
used as validation set to evaluate the algorithm performance. Next, we swapped the cohorts 
previously used as training and validation. The genes were then extracted that appeared in both the 
training set based gene signature lists, and formed the IPA gene signature that consists of 18 genes. 
Similar process was repeated to form the N-IPA gene signature that consists of 106 genes.  
3.3 Prediction performance 
The performance of our method IPA, N-IPA was evaluated along with their comparison with gene 
signature generated using t-test (denoted as TGS). For performing the binary prediction tasks, the 
algorithms were applied on both FWC cohort and the BWC cohort. 
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First, we performed the binary prediction task of predicting
For the IPA gene signature, N-IPA gene signature
SVM-RBF classification technique performed well
However, performing the binary prediction task
consuming task. Therefore, the TreeBoost can be
consuming) to build the model compared wi
performance as SVM-RBF. The Figure 2 shows
performance measures of Accuracy, F-measure, 
algorithm (N-IPA) achieved lesser performance 
performance measures. Also, if comparing the algorithms
technique, the IPA algorithm achieved nearly the 
and Ttest. 
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 the ERp or ERn subclass of a sample. 
 and the TGS gene signature, the TreeBoost and 
 amongst the other classification techniques. 
 with SVM is more computationally time-
 chosen as an optimal classifier (being less-time 
th SVM, and also showed better prediction 
 the IPA algorithm achieved overall best 
and AUC. In contrast, the network based IPA 
measures, and further, the Ttest achieved worst 
 considering the different classification 
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Fig.2. Line charts shows the performance measures
FWC and BWC cohort for the different prediction
subclass.Here, the Avg for an algorithm denotes
as averaging the performance measure from
Next, we performed the binary prediction task of 
of a sample. As mentioned previously, the TreeBoost
in this case amongst the other classification techniques
shows the IPA algorithm still achieved overall best
Ttest. However, in this case, if considering the individual
N-IPA algorithm performed nearly similar and contrasting
overall performance measures, the IPA algorithm
measures and their difference is statistically non-significant
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 of Accuracy, F-measure, and AUC in 
 algorithms that predict ERp/ERn binary 
 the overall average performance, calculated 
 all the different classification techniques.   
predicting the pCR or npCR treatment response 
 classification technique also performed well 
 in each of the algorithms. The Figure 3 
 performance measures, followed by N-IPA and 
 classification technique, the IPA and the 
 each other. Also, if considering the 
 achieved marginally better performance 
 (p-value>0.05).  
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Fig. 3. Line charts shows the performance measures
FWC and BWC cohort for the different prediction
subclass.
The treatment response prediction of chemotherapy
[30], due to the differences that comes with the known
cancers or the variation in drug metabolism, dosage,
constructing the gene signatures for the prediction
more complex problem than predicting the subtypes
treatment response is more challenging task than
and this complexity can be overcome by incorporating
expressions [10, 33]. Also, from the above experiments,
network-based information improved the prediction
treatment prediction task, compared with performing
2 and Figure 3).  
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 algorithms that predict pCR/npCR binary 
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 of response to chemotherapy has shown to be a 
 of cancer [32]. Therefore, the prediction of 
 to predict the ERp/ERn breast cancer subclass, 
 interactions network into the gene 
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However, the protein interactions identified from the experiments usually contain false-positive 
interactions, i.e., the interactions in the experimental dataset but never happen in real biological 
processes. As a consequence, the discovered biological knowledge from the interaction networks 
may be biased. Therefore, the identification of reliable (or biologically valid) interactions is 
considered to be a challenging issue. The reliable interactions incorporated with gene expressions 
can significantly lead to improved predictive performance results with improved biological 
meaning associated with the genes in the gene signature [9]. 
Since, in the N-IPA algorithm, we directly incorporated the interaction network with the gene 
expression information without considering the reliability of the interactions. This may leads to 
biased results and possibly may be one of the potential reasons that N-IPA algorithm showed lesser 
overall performance measures than IPA algorithm for predicting ERp/ERn subclass and pCR/npCR 
subclass, respectively. However, if considering the reliability metrics (see [9] for details), then 
possibly the performance measures may get improved, which leads further investigations and will 
remain the part of our future work. 
Next, as the TreeBoost classification technique achieved best performance measures for each of the 
algorithm. Therefore for further analysis, we selected the best classification technique to perform 
the predictive task. The Figure 4 shows the IPA algorithm outperformed the other algorithms on 
the average (as well as individual cohort) performances in performing the prediction task of 
ERp/ERn with considering the best classification technique of TreeBoost. Similar results were 
achieved in Figure 5 when performing the prediction task of pCR/npCR with considering the best 
classification technique of TreeBoost. From Figure 5, it can be seen that the performance measures 
of IPA and N-IPA were close together and were consistent with the previously mentioned results as 
discussed above (Figure 3).  
 
Fig. 4. Bar charts show the performance measures of Accuracy, F-measure, and AUC for 
different prediction algorithms using the best classification technique of TreeBoost that 
predict ERp/ERn binary subclass.Here, the Avg for an algorithm denotes the overall average 
performance measure, calculated as averaging the performance measure from the FWC and 
BWC.   
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Fig. 5. Bar charts show the performance measures of Accuracy, F-measure, and AUC for 
different prediction algorithms using the best classification technique of TreeBoost that 
predict pCR/npCR binary subclass.   
In summary, the IPA algorithm based gene signature showed the best predictive performances and 
higher stability between different cohorts in performing the prediction of binary subclass with 
demonstrated their independency to the multiple classification technique, and therefore can be 
more clinically applicable to the patients from other independent cohorts. 
3.4 Reproducibility of predictive gene signatures 
We performed the reproducibility analysis of gene signatures derived from the IPA, the N-IPA, and 
the Ttest algorithm, and was performed by calculating the number of overlapping genes between 
them. There is an overlap of 12 genes (16.7-66.7%) between the IPA gene signature and the other 
gene signatures. This overlap is greater than the overlap of gene signatures between the N-IPA and 
the Ttest (2-9%). This reproducibility may contributing to the higher stability that achieved better 
predictive performances from the different cohorts, compared with the N-IPA and the Ttest 
algorithms 
3.5 Biological analysis of predictive gene signatures 
The biological analysis of the gene signatures was performed considering the gene ontology (GO) 
analysis by using the Ingenuity Pathway Analysis Software (IPA) (http://www.ingenuity.com/). For 
each gene in the gene signature, GO analysis was performed using the enriched biological process 
GO terms [34].  
Figure 6 lists the enriched biological process associated with the gene signatures along with their p-
values. The Figure 6 shows many significantly enriched biological process for the N-IPA gene 
signature, including Cell Signaling, Apoptosis, DNA Replication, Recombination, and Repair, 
Drug Metabolism, besides others, which are the expected target biological processes that relates 
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with the treatment response for various anticancer drugs [10] and with the estrogen-receptor 
subclass. 
Further, it can be observed that the N-IPA gene signature is more biologically enriched compared 
with their counterpart IPA algorithm (see Figure 6). This biological analysis showed that the 
network based gene signatures are more significantly associated with the phenotype of interest, and 
the biological meaning of their gene signatures are meaningful and strongly related with the 
enriched biological processes associated estrogen–receptor subclass or chemotherapy response 
subclass.  
As mentioned previously, incorporating reliability metrics into the interaction network may further 
enhance the performance results (see Section 3.3), which may also improve the association of their 
gene signatures with the enriched biological process, significantly. 
 
Fig. 6. Enriched biological process based GO functions for the IPA, N-IPA, and Ttest 
algorithm based gene signatures. Here, Ttest-ERp/ERn stands for the Ttest algorithm based 
gene signature for predicting the binary estrogen receptor subclass, and Ttest-pCR/npCR 
stands for the Ttest algorithm based gene signature for predicting the binary chemotherapy 
response subclass. The y-axis shows the logarithm of p-values evaluated from the Fisher exact 
test, with a threshold for statistical significance of p-value=0.05 represented by the thin 
horizontal red line. 
4. CONCLUSION 
In this study, we derived the gene signatures from our proposed algorithm, IPA and their network-
based variant, N-IPA from different cohort of breast cancer patients, which demonstrated the 
effectiveness of the proposed algorithm in predicting the binary estrogen-receptor subclass and 
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predicting the binary chemotherapy treatment response subclass with considering multiple 
classification techniques. Further, we also demonstrated the effectiveness of considering the 
network-based information in performing the binary prediction task.  
From our statistical and biological analyses, we suggest that our proposed algorithm, IPA may 
serve as better clinical predictors in performing the prediction tasks. While the initial conclusions 
such as these are motivating, further detailed study is needed with increased samples coverage. 
Since, in the N-IPA algorithm we did not consider the reliability metrics that can extract the 
biologically relevant (or true interactions) by removing the false-positive interactions, which will 
improve the performance results. This is worthwhile investigating in our future work along with the 
comparison of existing popular network based algorithms that considered reliability metrics. 
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